Testing for Drug-Related Infectious Diseases and Determinants among People Who Use Drugs in a Low-Resource Setting: A Respondent-Driven Cross-Sectional Survey.

Journal: Tropical medicine and infectious disease

Volume: 7

Issue: 9

Year of Publication: 

Affiliated Institutions:  Department of Epidemiology and Biostatistics, Muhimbili University of Health and Allied Sciences, Dar es Salaam , Tanzania. Department of Behavioural Sciences, Muhimbili University of Health and Allied Sciences, Dar es Salaam , Tanzania. Audrey and Theodor Geisel School of Medicine at Dartmouth, Hanover, NH , USA. Schools of Public Health, Boston University, Boston, MA , USA. Department of Community Medicine and Global Health, Institute of Health and Society, University of Oslo, NO- Oslo, Norway. Global Health Section, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.

Abstract summary 

(1) Background: There is a dearth of data on the levels and determinants of testing for drug-related infectious diseases among people who use drugs (PWUD). We assessed the proportions and determinants of testing for drug-related infectious diseases to inform ongoing interventions for PWUD. (2) Methods: A cross-sectional study involving 599 PWUD was conducted in Dar es Salaam and Tanga between January and February 2019. Data were collected through a researcher-administered questionnaire using handheld tablets. Logistic regression models were used to identify independent testing determinants for drug-related infectious diseases. (3) Results: A majority (98.0%) of participants were males, with a mean age of 36.8 (SD = 7.8) years. 75.0%, 40.6%, 38.6%, and 8.2% reported having ever tested for HIV, tuberculosis (TB), sexually transmitted infections (STIs), and viral hepatitis, respectively. The likelihood of HIV testing was higher among those living with someone (AOR = 2.18, 95% CI: 1.09-4.68) compared with those who were homeless and perceived treatment was appropriate (AOR = 2.18, 95% CI: 1.05-4.46), but was lower among those who experienced mild to moderate (AOR = 0.44, 95% CI: 0.21-0.95) and severe internalized stigma (AOR = 0.44, 95% CI: 0.22-0.94) compared with those reporting no internalized stigma, and among those who experienced financial difficulties resulting from spending on health care services (AOR = 0.60, 95% CI: 0.40-0.89). Perception of treatment appropriateness (AOR = 2.29, 96% CI: 1.10-5.06) and severe enacted stigma (AOR = 1.90, 95% CI: 1.06-3.42) were associated with increased odds of TB testing. The odds of STIs testing increased among those who were married (AOR = 2.31, 95% CI: 1.45-3.72) compared with those who were single and those who had experienced mild (AOR = 2.39, 95% CI: 1.28-4.53) or severe (AOR = 6.20, 95% CI: 1.99-23.83) sexual violence, compared with those who had not experienced sexual violence. However, the odds decreased among those who had been remanded in the past month (AOR = 0.64, 95% CI: 0.43-0.95) compared with those who were not remanded and among those who had financial difficulties resulting from spending on health care services (AOR = 0.66, 95% CI: 0.47-0.94). The likelihood of testing for viral hepatitis testing increased among those who had heard about the comprehensive HIV intervention package (CHIP) (AOR = 2.59, 95% CI: 1.40-4.94); however, it decreased among those who had financial difficulties resulting from spending on health care services (AOR = 0.48, 95% CI: 0.24-0.92). (4) Conclusions: Except for HIV, PWUD had undergone limited testing for drug-related infectious diseases. The study findings highlight some factors influencing testing for the selected infectious diseases investigated, which should be targeted for tailored interventions to improve diagnosis and treatment.

Authors & Co-authors:  Likindikoki Samuel Lazarus SL Mmbaga Elia J EJ Mizinduko Mucho M Alexander Mwijage M Adams Lisa V LV Horsburgh Robert R Moen Kåre K Leyna Germana G Lange Theis T Tersbøl Britt P BP Leshabari Melkizedeck M Meyrowitsch Dan W DW

Study Outcome 

Source Link: Visit source

Statistics
Citations :  United Nations Office on Drugs and Crime . World Drug Report 2020. 1. Executive Summary: Impact of COVID-19. Policy Implications. United Nations; New York, NY, USA: 2020. [(accessed on 31 July 2022)]. 56p. United Nations Publication, Sales No. E.20.XI.6. Available online: https://wdr.unodc.org/wdr2020/field/WDR20_BOOKLET_1.pdf.
Authors :  12
Identifiers
Doi : 213
SSN : 2414-6366
Study Population
Male,Female
Mesh Terms
Other Terms
HIV;PWUD;STIs;TB;Tanzania;infectious diseases;low-resource setting;testing;viral hepatitis
Study Design
Cross Sectional Study
Study Approach
Country of Study
Publication Country
Switzerland